AstraZeneca's Alexion Gets Positive EU Recommendation for Klygefa in Rare Muscle Disease

10:03 AM EDT, 09/18/2026 (MT Newswires) -- AstraZeneca (AZN) said Friday that Alexion, AstraZeneca Rare Disease's Klygefa received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval in the European Union. Klygefa is intended to treat adults with generalized myasthenia gravis, a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness. The opinion was supported by data from the phase 3 PREVAIL trial, which the company said demonstrated the efficacy and safety profile of the long-acting C5 complement inhibitor in patients with the disease. Price: 166.82, Change: +0.68, Percent Change: +0.41